5.0 Reviews
Ac-Nle-cyclo[BremelanotideVyleesi
A 7-amino acid cyclic peptide analog of alpha-MSH that activates melanocortin receptors MC3R and MC4R, FDA-approved for hypoactive sexual desire disorder and studied for sexual function in clinical research. Premium Research Peptide.
$75.00
We accept :
Third Party Tested by Freedom Diagnostics
The Science, Simplified
Gene Expression
Epigenetic Modulation
Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways
Gene Expression
Epigenetic Modulation
Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways
Gene Expression
Epigenetic Modulation
Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways
Key insight: This sudden release of nitric oxide relaxes smooth muscle tissue and dilates local blood vessels. In male models, this neural cascade has shown a rapid, dose-dependent improvement in erectile rigidity and duration, making it a valuable subject for treating erectile dysfunction (ED) where typical PDE5 inhibitors (like Viagra) have failed.
Key insight: Clinical research shows it explicitly corrects Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. By bridging the gap between mechanical blood flow and neurochemical desire, it serves as a dual-action model for comprehensive reproductive health studies.
What clinical studies report
PT-141 has undergone comprehensive clinical evaluation and earned FDA approval under the brand name Vyleesi for specific clinical indications, establishing a highly documented safety profile.
🧿 Common Digestive Issues
Nausea
mild
Flushing
mild
Headache
mild
Safety Advantage
Cardiovascular Alternative
📊 Discontinuation Rates
🚫 Trial Exclusions
⚡ Regulatory Status
💡 Researcher Notes
Technical specifications
🔬 Molecular Profile
What Is PT-141?
Type
Cyclic heptapeptide
CAS Number
189691-06-3
Molecular Formula
C50H68N14O10
Molecular Weight
1025.2 g/mol
Amino Acids
7 residues
Sequence
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
🧊 Storage Requirements
Stability Information
Developed by Palatin Technologies, approved by FDA
Lyophilized (powder)
2-8°C
protect from light
Reconstituted
2-8°C
use within 30 days
Auto-injector (Vyleesi)
Room temperature
Development Status
Regulatory Information
Developed by Palatin Technologies, approved by FDA
Developer
Palatin Technologies
Marketing
AMAG Pharmaceuticals
FDA Approval
June 21, 2019
Trade Name
Vyleesi
Indication
Not approved (research only)
Common questions about PT-141
Peer-reviewed research
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
